Latest News and Press Releases
Want to stay updated on the latest news?
-
Advancing small molecule therapeutic candidates with clinical and preclinical data suggesting potential neuroprotective, neurotrophic, procognitive and disease-modifying effects Fosgonimeton Phase...
-
BOTHELL, Wash., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
-
ATH-1105 demonstrated consistent improvements across measures of motor function, nerve function, and neurodegeneration in a TDP-43 mouse model of ALS Data adds to the growing body of evidence...
-
BOTHELL, Wash., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
-
Fosgonimeton treatment-related reductions in biomarkers of neurodegeneration (NfL) and neuroinflammation (GFAP) significantly correlated with improvements in clinical outcomes as assessed by the GST,...
-
BOTHELL, Wash., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
-
BOTHELL, Wash., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
-
Fosgonimeton treatment showed results suggestive of neuroprotection and potential disease modification in models of Parkinson’s disease Small molecule positive modulators of HGF/MET improved symptoms...
-
Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
Independent, unblinded, interim efficacy and futility analysis of Phase 2/3 LIFT-AD study in mild-to-moderate Alzheimer’s disease patients supports potential clinically meaningful activity of...
-
BOTHELL, Wash., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...